Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 May;2(5):44.
doi: 10.3978/j.issn.2305-5839.2014.05.06.

Phase II trial of temozolomide and reirradiation using conformal 3D-radiotherapy in recurrent brain gliomas

Mohammed A M Osman  1
Affiliations

Phase II trial of temozolomide and reirradiation using conformal 3D-radiotherapy in recurrent brain gliomas

Mohammed A M Osman. Ann Transl Med. 2014 May.

Abstract

Purpose: This phase II trial was designed to assess the response rate, survival benefits and toxicity profile of temozolomide, and brain reirradiation using conformal radiotherapy (RT) for treatment of recurrent high grade glioma.

Design: Open-label phase II trial.

Patients: Twenty-nine patients had been enrolled in the study between February 2006 and June 2009. Patients had to show unequivocal evidence of tumour recurrence on gadolinium-enhanced magnetic resonance imaging (MRI) after failing conventional RT with or without temozolomide and surgery for initial disease. Histology included recurrent anaplastic astrocytoma, glioblastoma multiforme.

Interventions: Patients were treated by temozolomide at a dose of 200 mg/m(2)/day for chemonaïve patients, and at a dose of 150 mg/m(2)/day to previously treated patients, for 4-5 cycles. Then, patients underwent reirradiation by conformal RT at a dose of 30-40 Gy by conventional fractionation.

Main outcome measures: The primary end point of the study was response. The secondary end points included survival benefit.

Results: All the 29 patients were treated with temozolomide and reirradiation. Two patients achieved complete remission (CR), 4 achieved partial remission (PR), with an overall objective response rate of 20.6%, and further 10 patients had stable disease (SD), with a SD rate of 34.4%. The mean progression free survival (PFS) was 10.1 months, and the mean overall survival (OS) was 11.4 months. Additionally, treatment significantly improved quality of life (QOL). Treatment was tolerated well with mild grade 1, 2 nausea/vomiting in 40% of cycles, and mild grade 1, 2 haematological toxicities (neutropenia/thrombocytoprnia) in 8.6% of cycles.

Conclusions: Temozolomide and conformal RT had an anti-tumor activity in recurrent high grade glioma, and represented a good treatment hope for patients with recurrent brain glioma.

Keywords: Reirradiation; glioma; quality; recurrent; survival; temozolomide.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Treatment protocol of the current study.
Figure 2
Figure 2
Quality of life (QOL) score changes in our study (P value was 0.0001).
Figure 3
Figure 3
MRI before treatment protocol.
Figure 4
Figure 4
MRI after treatment protocol.
See this image and copyright information in PMC

References

    1. Brandes AA, Vastola F, Monfardini S. Reoperation in recurrent high-grade gliomas: literature review of prognostic factors and outcome. Am J Clin Oncol 1999;22:387-90. - PubMed
    1. Melissa LB, El-Zein R, Scheurer ME. Epidemiology of brain tumors, Chapter1. In Tumors of the brain and spine. M.D. Anderson Cancer Care Series. eds. DeMonte F, Gilbert MR, Mahajan A, et al. Springer Science Business Media, USA, 2007.
    1. van den Boom J, Wolter M, Kuick R, et al. Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am J Pathol 2003;163:1033-43. - PMC - PubMed
    1. Dillon A. Guidance on the use of temozolomide for the treatment of recurrent malignant glioma. (brain cancer). NICE Technology Appraisal Guidance – No.23, 2001. National Institute for Clinical Excellence, UK.
    1. Osoba D, Brada M, Yung W.Temozolomide May Improve the Outlook for Patients with Recurrent Malignant Gliomas. Drug Ther Perspect 2000:15:1-5